Mitochondria are pertinent targets for efficient drugs, cosmetics or functional food for better health and safer products. Find out how our tests can help advance your projects in demonstrating mechanisms of action and getting pre-clinical proof of principle.
ICDD is set to identify blood makers specifically for presymptomatic stages of neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington’s disease using cellulomics in innovative patient-derived cell models & blood protein profiling.
You have a drug that target CNS diseases and cancers. We have companion diagnostic tests and platforms to identify subset of patients that respond to and tolerate your drug. Let’s work together to advance patient health and disease clinical management.
HARNESSING THE POWER OF SYSTEM BIOLOGY
Understanding complex processes and their dynamics is how ICDD progresses toward the identification of new candidate biomarkers associated with disease progression and/or drug response.
What we do
ICDD in the news
DHUNE, un centre d'excellence avec les maladies neuro-dégénératives en ligne de mire Une entreprise du pays d'aix va transformer la maladie d'Alzheimer en mauvais souvenir Elle repère les premiers signes d'Alzheimer dans le sang et la peau Quatre innovations époustouflantes Anti-Aging: Protection strategies for mitochondria Predicting Drug Toxicity in Humans (page 2) Novel ADMET (Absorption, Distribution, Metabolism, Elimination, and Toxicity) Technologies Gain Traction
Read our clients' and partners' publications (articles, white papers, websites, press releases, etc.) referring to the results obtained using ICDD's technologies and/or expertise.